American Battery Solutions, Inc.’s ESS Division Completes Spin-Out, Establishes American Energy Storage Innovations, Inc.

The new independent company charts enormous success with industry leader Bud Collins at the helm.

BOSTON and DETROIT, Sept. 11, 2023 (GLOBE NEWSWIRE) — Today, just ahead of the RE+ exhibition, American Battery Solutions, Inc. (ABS) is pleased to announce the spin-out of its Energy Storage Solutions Division (ABS-ESS) to create a new company: American Energy Storage Innovations, Inc. (AESI). This strategic move represents a significant milestone in the evolution of energy storage technology and underscores ABS’ commitment to driving innovation within the industry.

ABS was founded just four years ago by Subhash Dhar, a venerable 40-year battery industry veteran, and has consistently led the charge to advance cutting-edge energy storage technologies. Dhar, who remains actively engaged as a board member of the new venture, emphasized, “We nurtured and honed the unique potential embodied by TeraStor when we established the ESS Division, announced publicly just last year. Today, we fully recognize its potential, and are exhilarated to witness the autonomous ascent of AESI.”

AESI (RE+ exhibitor booth 13100) will operate as a fully independent company, enjoying the continued support, confidence and backing of ABS’ longstanding investors, the KCK Group. With an unwavering commitment to revolutionizing energy storage, AESI is poised to take center stage in the global energy transition and is set to redefine the future of energy storage technology.

The board of directors made the strategic decision to establish AESI as a distinct corporation, recognizing the incredible potential of the team’s groundbreaking technology and the immense growth opportunities on the horizon. By focusing exclusively on energy storage innovation, AESI will be better equipped to respond to the evolving demands of the market, accelerate technological advancements and drive the transition to sustainable energy solutions.

AESI will be helmed by Bud Collins, a highly respected industry leader with over 35 years of experience in developing and implementing power, energy and energy management solutions. Under his direction, AESI will draw upon the expertise of the same management team and technical experts who have played pivotal roles in ABS-ESS since its establishment in 2021. This core team of industry veterans has a longstanding working relationship with Collins, having collaborated at multiple companies, and together they have collectively overseen the successful execution of more than 1.5 gigawatt-hours of energy storage projects over the past 15+ years, worldwide.

What sets AESI apart is its inheritance of the extensive resources and capabilities developed within ABS-ESS, coupled with a dedicated institutional focus on pioneering energy storage technologies. AESI is committed to pushing the boundaries of innovation in energy storage and remains steadfast in its mission to drive sustainability and usher in a new era of energy solutions.

“We are thrilled to embark on this new journey as American Energy Storage Innovations,” said Collins, CEO of AESI. “Our team’s collective expertise and dedication to innovation will allow us to build on the strong foundation we created as ABS-ESS and make a significant impact on the energy storage industry. With the continued support of the KCK Group, we are poised to achieve remarkable success in shaping the future of energy storage technology.”

This announcement marks a successful exit for ABS-ESS and represents a pivotal moment in the energy storage industry, signaling a commitment to innovation and sustainability. As AESI begins its journey as an independent company, it remains dedicated to pushing the boundaries of what is possible in energy storage, driving the global energy transition to new heights.

For more information on AESI and the 7.2 MWh (300MWh/acre) TeraStorTM, please visit booth 13100 at the RE+ exhibition or visit https://www.aesi-ess.com.

About American Energy Storage Innovations, Inc.
AESI is a pioneering provider of advanced energy storage solutions. The company designs, develops and manufactures cutting-edge systems, empowering customers to harness the full potential of renewable energy and optimize energy management. With a steadfast commitment to value, reliability, sustainability and innovation, the AESI team of industry veterans aims to revolutionize the energy storage landscape.

Contact
AESI Media Relations
American Energy Storage Innovations, Inc.
2 Cabot Road, Hudson, MA 01749 USA
media@aesi-ess.com

GlobeNewswire Distribution ID 8919936

Duck Creek Technologies Announces New Chief Financial Officer

Company appoints Teresa M. Kim, experienced technology finance executive, to oversee finance and accounting functions

Duck Creek Technologies Announces New Chief Financial Officer

Teresa Kim, Duck Creek Technologies CFO

BOSTON, Sept. 11, 2023 (GLOBE NEWSWIRE) — Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, announces the appointment of Teresa M. Kim as chief financial officer (CFO). Kim is an accomplished senior finance leader with a strong background and history in cloud computing, technology platforms, and “Big Four” public accounting. She joins Duck Creek following a 20-year tenure with Akamai Technologies (Akamai), a worldwide content delivery network and cloud service company, where she most recently served as vice president (VP) of finance in their cloud technology group overseeing $2 billion-plus in revenues while helping the business to build a scaling world-class platform. While at Akamai, she also was VP of finance in their media and carrier division helping to lead strategic media customer contract negotiations. Previously, she held a role as assistant controller overseeing global accounting and operations leading a large team of 120 professionals and building out finance centers of excellence in India and Poland.

Prior to Akamai, Kim served as a senior auditor with Ernst &Young (EY), supporting clients in EY’s technology, communications, and entertainment sector. She began her career in financial consulting roles with KPMG and Economic Analysis Corporation before moving into public accounting.

“Teresa is a dynamic and thoughtful leader with strong financial acumen, client focus, and experience across cloud and platform technology operations. As Duck Creek continues to focus on international growth and SaaS maturity, she will be a tremendous asset in helping to direct our own strategic transformation and optimize our financial operations,” said Mike Jackowski, CEO of Duck Creek. “This is an exciting time for all of us at Duck Creek and I am confident her talent will help us to continue creating value for our customers, partners, and stakeholders.”

Kim adds, “I’m excited to join Duck Creek as it strengthens its leadership position in the global insurance industry. I’m honored to have the opportunity to work closely with Mike and the entire Duck Creek team during a period of accelerated growth.”

Kim earned her Bachelor of Arts degree with a focus in economics and minor in Asian American studies from UCLA. She earned her MBA and a master’s degree in accounting from Northeastern University. Kim is based in the greater Boston area.

About Duck Creek Technologies

Duck Creek Technologies is the intelligent solutions provider defining the future of the property and casualty (P&C) and general insurance industry. We are the platform upon which modern insurance systems are built, enabling the industry to capitalize on the power of the cloud to run agile, intelligent, and evergreen operations. Authenticity, purpose, and transparency are core to Duck Creek, and we believe insurance should be there for individuals and businesses when, where, and how they need it most. Our market-leading solutions are available on a standalone basis or as a full suite, and all are available via Duck Creek OnDemand. Visit www.duckcreek.com to learn more. Follow Duck Creek on our social channels for the latest information – LinkedIn and Twitter.

Contact

Drake Manning
Duck Creek Technologies
drake.manning@duckcreek.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4a0ac0b9-1a79-4e33-a4bb-d27139e4383d

GlobeNewswire Distribution ID 8919541

WillScot Mobile Mini Announces $500 Million Senior Secured Notes Offering

PHOENIX, Sept. 11, 2023 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible space and storage solutions, today announced that its indirect subsidiary Williams Scotsman, Inc. (“WSI”) plans to offer, subject to market and other conditions, $500 million aggregate principal amount of senior secured notes due 2031 (the “Notes”). The Notes will be WSI’s general second lien senior secured obligations, guaranteed on a senior secured basis by each of WSI’s direct and indirect domestic subsidiaries that guarantees WSI’s obligations under the existing ABL credit facility and WSI’s direct parent, Williams Scotsman Holdings Corp.

WSI intends to use the net proceeds of the offering to repay approximately $494 million of outstanding indebtedness under its existing ABL credit facility and to pay related fees and expenses.

The Notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act. The Notes and the related guarantees will not be registered under the Securities Act or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About WillScot Mobile Mini

WillScot Mobile Mini trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible space and storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 240 branch locations and additional drop lots throughout the United States, Canada, and Mexico.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook,” “guidance,” “see,” “have confidence” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to the timing and conduct of the offering of the Notes, the size and terms of the offering of the Notes and the closing of the offering of the Notes. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, risks and uncertainties related to market conditions, that the size of the offering of the Notes could change or the offering of the Notes could be terminated, and the satisfaction of customary closing conditions related to the offering of the Notes. Any forward-looking statement speaks only at the date on which it is made, and the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information
Investor Inquiries: Media Inquiries:
Nick Girardi Jake Saylor
investors@willscotmobilemini.com jake.saylor@willscot.com

GlobeNewswire Distribution ID 8919855

New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance

– INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection

MELBOURNE, Australia and MILAN, Italy, Sept. 11, 2023 (GLOBE NEWSWIRE) — ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunomodulator in development for the prophylaxis of complications associated with respiratory viral infections. As previously reported, data from post-hoc analyses excluding those with pre-existing immunity against the challenge virus strain showed that INNA-051-treated participants with laboratory-confirmed infection had a statistically significant shorter duration of infection. New data reported today show that in this population, INNA-051 resulted in early stimulation of multiple genes that play important roles in the response to viral infections, including type I and III interferons. These results support the observed accelerated viral clearance. The biomarker data were presented in a late-breaking abstract oral session and the clinical data were discussed at a poster session at the European Respiratory Society meeting, which is taking place in Milan, Italy, September 9-13.

“The data presented today support the clinical potential of INNA-051 in individuals at risk for more severe outcomes resulting from viral respiratory infections,” said Christophe Demaison PhD, Managing Director and CEO of ENA Respiratory. “These data provide important insights into the molecular mechanisms that underlie the observed decrease in duration of infection in this flu challenge study. Together with our Phase 1 and preclinical data, the results provide a clear rationale for the continued clinical development of INNA-051 in the context of natural respiratory tract infections in individuals with increased risk of severe illness.”

The Phase 2a flu challenge study included 123 adults (ages 19 to 53) randomized to receive two doses of INNA-051 (low and high dose) or placebo, then challenged with a substantial dose of H3N2 (A/Perth/16/2009) influenza A virus.

Clinical results from the study were presented in a poster titled “INNA-051 pre-exposure prophylaxis in a human influenza infection model” (Poster #40831). INNA-051 safety and tolerability profile in the influenza challenge study was found to be consistent with data from Phase I in adults aged 18-80 and further supports its use in a prophylaxis setting.

Key findings from post hoc analyses conducted on participants with PCR-confirmed infection and no or low antibody titer against the challenged virus at quarantine admission, include:

  • Statistically significant reduction in the duration of viral shedding as measured by qRT-PCR detectable viral nucleic acid in the INNA-051 high-dose group relative to placebo.
  • Trend towards a shorter duration of clinical symptoms with the INNA-051 high dose.

Additional data from the study were presented in a late-breaking oral presentation titled “INNA-051 prophylaxis enhances innate immune responses confirming accelerated viral clearance in a human influenza challenge model” (Abstract #42457). Expression of 730 immune genes was assessed in nasal swabs obtained following influenza challenge from participants included in the post-hoc analysis. Key findings include:

  • Early increase in the expression of genes involved in the influenza host response in the INNA-051 treatment group compared to placebo, including genes for proteins known to have direct antiviral effects against influenza.
  • Higher early expression of key interferon genes in the INNA-051 treatment group compared to placebo.

“These findings clearly demonstrate that INNA-051 is associated with increased stimulation of multiple genes and pathways known to play essential roles in the innate immune response against influenza and is consistent with the accelerated viral clearance observed in the clinical efficacy data,” said Ruth Tal-Singer PhD, Medicine Development Leader, ENA Respiratory. “The continued evolution of respiratory viruses like those that cause long-COVID or influenza complications further underscores the critical need for novel approaches to boosting innate immunity against respiratory infections in vulnerable populations The data reported today increase our confidence that INNA-051 has the potential to play an important role in preventing or mitigating the severity of viral respiratory diseases.”

A Phase 2b study in community-acquired infections in people at risk of complications is planned.

Notes to Editors

If you would like to arrange an interview, please contact:

About ENA Respiratory and INNA-051

ENA Respiratory is a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants. ENA Respiratory is based in Melbourne and Sydney, Australia, and it has secured a Series A investment from Brandon Capital Partners’ managed funds, the Minderoo Foundation, and Uniseed.

In 2022, ENA Respiratory partnered with the US-based COPD Foundation to accelerate the clinical development of INNA-051 in COPD through its access to patients, a global network of accredited centres, scientific expertise, and patient investigators. That year, the company was also the first in the Asia Pacific region to be selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate next-gen potential solutions for future pandemics. In 2023, the company was additionally awarded a USD4.38 million contract from the U.S. Department of Defense to support the ongoing development of INNA-051.

INNA-051 is a potent TLR2/6 agonist that is delivered using a convenient nasal spray to target the preferential site of initial replication of viral respiratory infections. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. In preclinical studies, INNA-051 and close analogues were shown to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

For more information, please visit https://enarespiratory.com.

GlobeNewswire Distribution ID 8912092

Arbor Metals Commences Exploration at Jarnet Lithium Project, Quebec, Canada

Map of Arbor Metal Corp.’s Jarnet Lithium Claims

Arbor’s Jarnet Lithium Mine is located in the James Bay region of Quebec and is comprised of 47 map-designated claims that cover an approximate area of 3,759 hectares.

VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) — Arbor Metals Corp. (“Arbor” or the “Company”) (TSXV: ABR, FWB: 432 is pleased to announce the deployment of its exploration team to the Company’s Jarnet lithium project in the James Bay region of Quebec, Canada. The exploration program spans several days and will encompass mapping, prospecting activities and drilling of potential targets. The team will be stationed at a lodge in Northern Quebec, strategically situated near the project claims, to ensure efficient access to the site via helicopter. A qualified Quebec geologist will oversee the program, conducting a final verification and preparing an assessment report.

Incorporating the latest technological advancements, the Company has integrated a laser-induced breakdown spectroscopy (LIBS) laser spectrometer into the exploration program. This cutting-edge technology will play a pivotal role in expediting the assessment of whether lithium-bearing minerals exist within the pegmatite dikes on the Company’s Jarnet lithium project.

The LIBS laser spectrometer is specifically designed to identify and assess lithium-containing minerals, focusing on minerals like spodumene. This advanced instrument utilizes a pulsed laser to transform a sample into a plasma state, followed by optical analysis across various wavelengths, including visible light, ultraviolet (UV) and infrared (IR) spectrums. Renowned for its accuracy and reliability, the LIBS analytical approach has delivered consistent success for lithium exploration efforts in various lithium-rich regions worldwide, including the Corvette Lake camp.

Mark Ferguson, President and CEO of Arbor, expressed his excitement as the Company’s 2023 exploration program kicks off. He commended his team for their proactive approach in revising the exploration plan to ensure the successful completion of the program despite the delays caused by the wildfires that swept through Quebec over the summer. Ferguson also conveyed his gratitude to the firefighters and other dedicated individuals who worked tirelessly to combat the wildfires.

Management Update

The Company’s annual general and special meeting on August 11, 2023, approved all presented matters. Following the meeting, Richard Ko assumed the position of Chief Financial Officer and Corporate Secretary of the Company.

Arbor remains dedicated to its exploration endeavours and will provide updates as the program progresses.

Technical aspects of this news release have been reviewed, verified and approved by Dr. Peter Born, P.Geo, a Director of Arbor and a qualified person as defined in NI 43-101.

About Arbor Metals Corp.

Arbor Metals Corp. is a mining exploration company focused on developing high-value, geographically significant mineral projects worldwide. Arbor is paving the way for advanced mineral exploration as it oversees world-class mining projects. The Company is confident that combining quality projects with proven strategies and a dedicated team will yield exceptional outcomes. Arbor currently oversees three outstanding mineral projects.

Map of Arbor Metal Corp.'s Jarnet Lithium Claims

For further information, contact Mark Ferguson, Chief Executive Officer, at info@arbormetals.com, or 403-852-4869 or visit the Company’s website at www.arbormetalscorp.com.

On behalf of the Board,

Arbor Metals Corp.

Mark Ferguson, Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When or if used in this news release, the words “anticipate,” “believe,” “estimate,” “expect,” “target, “plan,” “forecast,” “may,” “schedule,” and similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to planned project development, exploration programs, success of the LIBS analytical approach and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

MRKT360 INC
https://mrkt360.com
Alex Zertuche
alexz@mrkt360.com
For E.S.T Office Hours, Call 1 416-477-0587

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1ac9c34f-6084-4782-a8ec-1c2f30b35a1a

GlobeNewswire Distribution ID 8919155

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

  • Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America
  • Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars

INCHEON, Korea, Sept. 11, 2023 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelarai (ustekinumab), marking a step forward in strengthening access to Samsung Bioepis’ immunology portfolio in the United States (US), Canada, European Economic Area (EEA), Switzerland and United Kingdom (UK).

“This agreement is a testament to Samsung Bioepis’ strong track record in the field of immunology, demonstrating a potential value that our biosimilars could deliver for widening access to biologic medicines.” said Sang-Jin Pak, Executive Vice President and Head of Commercial Division, at Samsung Bioepis.

SB17, a proposed biosimilar to Stelara (ustekinumab), is Samsung Bioepis’ fourth candidate in its immunology pipeline, following SB4 (etanercept), SB2 (infliximab) and SB5 (adalimumab). Samsung Bioepis has a more than 5-year track record of supplying over 48 million units of immunology biosimilars in nearly 40 markets across the world.

In March, the company presented Phase 1 clinical study results of SB17 at the 2023 American Academy of Dermatology (AAD) Annual Meeting, which demonstrated pharmacokinetics (PK) equivalence and comparable safety, tolerability, immunogenicity profiles between SB17 and reference ustekinumab. SB17 Phase 3 clinical study results are set to be presented at a medical congress this year as Phase 3 study was completed in December 2022.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.

i Stelara is a trademark of Janssen Pharmaceuticals.

MEDIA CONTACT

Jane Chung: ejane.chung@samsung.com
Anna Nayun Kim, nayun86.kim@samsung.com

GlobeNewswire Distribution ID 8919597